Skip to main content
. 2018 May 18;18(2):135–147. doi: 10.3727/105221618X15174108894682

Figure 3.

Figure 3

EMD1214063 does not impact β-catenin signaling in the Met-β-catenin model. (A) Microscopic foci show positivity for glutamine synthetase (GS) in the control- and EMD1214063-treated groups at both 8 and 11 weeks. (B) Quantification of immunostaining showed lack of any differences in the control and experimental group at either or both time points after EMD1214063 treatment. (C) EMD1214063 treatment showed a marginal decrease in total GS levels by Western blot analysis at only 8 weeks. GAPDH shows comparable loading in all lanes.